The role of intravenous iron in the treatment of anemia in cancer patients

Therapeutic Advances in Hematology

Volumn 3, Issue 3, 2012, Pages 177-191

  Steinmetz, H Tilman ^a  

^a Outpatient Clinic for Oncology and Haematology   (Germany)

Author keywords

anemia of chronic disease; cancer; hemoglobin; iron deficiency

Indexed keywords

C REACTIVE PROTEIN; CYANOCOBALAMIN; ERYTHROPOIETIN; FERRIC GLUCONATE; FERRITIN; FOLIC ACID; HAPTOGLOBIN; HEMOGLOBIN; INTERLEUKIN 6; IRON; LACTATE DEHYDROGENASE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; TRANSFERRIN; TRANSFERRIN RECEPTOR; TUMOR NECROSIS FACTOR;

ANEMIA; ARTICLE; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMORADIOTHERAPY; CHRONIC KIDNEY DISEASE; CLINICAL STUDY; CONSTIPATION; CREATININE CLEARANCE; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HEMOLYTIC ANEMIA; HUMAN; IRON DEFICIENCY; IRON THERAPY; KIDNEY FAILURE; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; RETICULOCYTE; TREATMENT RESPONSE; UTERINE CERVIX CANCER; VITAMIN DEFICIENCY;

EID: 84993815497     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620712440071     Document Type: Article

References (62)

1. Aapro M. Beguin Y. Birgegard G. Gascon P. Hedenus M. Osterborg A. (2011) Too-low iron doses and too many dropouts in negative iron trial? J Clin Oncol 29: e525-e526; author reply e527–e528.
2. Aapro M.S. Link H. (2008) September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 13(Suppl. 3): 33–36.
3. Auerbach M. Ballard H. Glaspy J. (2007) Clinical update: intravenous iron for anaemia. Lancet 369: 1502–1504.
4. Auerbach M. Ballard H. Trout J.R. McIlwain M. Ackerman A. Bahrain H. et al. (2004) Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 22: 1301–1307.
5. Auerbach M. Silberstein P.T. Webb R.T. Averyanova S. Ciuleanu T.E. Shao J. et al. (2010) Darbepoetin alfa 300 or 500 mug once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Am J Hematol 85: 655–663.
6. Bailie G.R. Clark J.A. Lane C.E. Lane P.L. (2005) Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant 20: 1443–1449.
7. Barrett-Lee P. Bokemeyer C. Gascon P. Nortier J.W. Schneider M. Schrijvers D. et al. (2005) Management of cancer-related anemia in patients with breast or gynecologic cancer: new insights based on results from the European Cancer Anemia Survey. Oncologist 10: 743–757.
8. Bastit L. Vandebroek A. Altintas S. Gaede B. Pinter T. Suto T.S. et al. (2008) Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 26: 1611–1618.
9. Beguin Y. (2002) Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients. Haematologica 87: 1209–1221.
10. Birgegard G. Gascon P. Ludwig H. (2006) Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY. Eur J Haematol 77: 378–386.
11. Bohlius J. Schmidlin K. Brillant C. Schwarzer G. Trelle S. Seidenfeld J. et al. (2009) Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 373: 1532–1542.
12. Bokemeyer C. Aapro M.S. Courdi A. Foubert J. Link H. Osterborg A. et al. (2007) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43: 258–270.
13. Brownlie T.t. Utermohlen V. Hinton P.S. Haas J.D. (2004) Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women. Am J Clin Nutr 79: 437–443.
14. Brugnara C. (2000) Reticulocyte cellular indices: a new approach in the diagnosis of anemias and monitoring of erythropoietic function. Crit Rev Clin Lab Sci 37: 93–130.
15. Cash J.M. Sears D.A. (1989) The anemia of chronic disease: spectrum of associated diseases in a series of unselected hospitalized patients. Am J Med 87: 638–644.
16. Cazzola M. Beguin Y. (1992) New tools for clinical evaluation of erythron function in man. Br J Haematol 80: 278–284.
17. Chertow G.M. Mason P.D. Vaage-Nilsen O. Ahlmen J. (2006) Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 21: 378–382.
18. Dangsuwan P. Manchana T. (2010) Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol 116: 522–525.
19. de Benoist B. McLean E. Egli I. Cogswell M. (2008) Worldwide Prevalence of Anaemia 1993–2005: WHO Global Database on Anaemia. Geneva, Switzerland: World Health Organization.
20. Dubray B. Mosseri V. Brunin F. Jaulerry C. Poncet P. Rodriguez J. et al. (1996) Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: a prospective study. Radiology 201: 553–558.
21. Fein D.A. Lee W.R. Hanlon A.L. Ridge J.A. Langer C.J. Curran W.J. Jr et al. (1995) Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol 13: 2077–2083.
22. Fishbane S. Frei G.L. Maesaka J. (1995) Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26: 41–46.
23. Glaser C.M. Millesi W. Kornek G.V. Lang S. Schull B. Watzinger F. et al. (2001) Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 50: 705–715.
24. Glaspy J. Bukowski R. Steinberg D. Taylor C. Tchekmedyian S. Vadhan-Raj S. (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 15: 1218–1234.
25. Glaspy J. Crawford J. Vansteenkiste J. Henry D. Rao S. Bowers P. et al. (2010) Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 102: 301–315.
26. Goodnough L.T. Nemeth E. Ganz T. (2010) Detection, evaluation, and management of iron-restricted erythropoiesis. Blood 116: 4754–4761.
27. Grotto H.Z. (2008) Anaemia of cancer: an overview of mechanisms involved in its pathogenesis. Med Oncol 25: 12–21.
28. Hedenus M. Birgegard G. Nasman P. Ahlberg L. Karlsson T. Lauri B. et al. (2007) Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 21: 627–632.
29. Henry D.H. Dahl N.V. Auerbach M. Tchekmedyian S. Laufman L.R. (2007) Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 12: 231–242.
30. Kim Y.T. Kim S.W. Yoon B.S. Cho H.J. Nahm E.J. Kim S.H. et al. (2007) Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol 105: 199–204.
31. Krause A. Neitz S. Magert H.J. Schulz A. Forssmann W.G. Schulz-Knappe P. et al. (2000) LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 480: 147–150.
32. Lee E.J. Oh E.J. Park Y.J. Lee H.K. Kim B.K. (2002) Soluble transferrin receptor (sTfR), ferritin, and sTfR / log ferritin index in anemic patients with nonhematologic malignancy and chronic inflammation. Clin Chem 48: 1118–1121.
33. Littlewood T.J. Bajetta E. Nortier J.W. Vercammen E. Rapoport B. (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19: 2865–2874.
34. Ludwig H. Müldür E. Endler G. Hübl W. Moneuse P. Klement B. (2011) High prevalence of iron deficiency across different tumors correlates with anemia, increases during cancer treatment and is associated with poor performance status. Haematologica 96: Abstract 982.
35. Ludwig H. van Belle S. Barrett-Lee P. Birgegard G. Bokemeyer C. Gascon P. et al. (2004) The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40: 2293–2306.
36. Macdougall I.C. Tucker B. Thompson J. Tomson C.R. Baker L.R. Raine A.E. (1996) A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50: 1694–1699.
37. Marx J.J. (2002) Iron and infection: competition between host and microbes for a precious element. Best Pract Res Clin Haematol 15: 411–426.
38. Mikhael J. Melosky B. Cripps C. Rayson D. Kouroukis C.T. (2007) Canadian supportive care recommendations for the management of anemia in patients with cancer. Curr Oncol 14: 209–217.
39. Mitchell D. (2010) A European Patient Record Study on Diagnosis and Treatment of Chemotherapy-induced Anaemia. Milan, Italy: ESMO.
40. NCCN (2012) Practice Guidelines in Oncology; Cancer and Chemotherapy-Induced Anemia. Available at: http://www.nccn.org/professionals/physician_gls/pdf/anemia.pdf.
41. Park C.H. Valore E.V. Waring A.J. Ganz T. (2001) Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 276: 7806–7810.
42. Pedrazzoli P. Farris A. Del Prete S. Del Gaizo F. Ferrari D. Bianchessi C. et al. (2008) Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 26: 1619–1625.
43. Pettersson T. Kivivuori S.M. Siimes M.A. (1994) Is serum transferrin receptor useful for detecting iron-deficiency in anaemic patients with chronic inflammatory diseases? Br J Rheumatol 33: 740–744.
44. Punnonen K. Irjala K. Rajamaki A. (1997) Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood 89: 1052–1057.
45. Rizzo J.D. Brouwers M. Hurley P. Seidenfeld J. Arcasoy M.O. Spivak J.L. et al. (2010 a) American Society of Clinical Oncology / American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 28: 4996–5010.
46. Rizzo J.D. Brouwers M. Hurley P. Seidenfeld J. Arcasoy M.O. Spivak J.L. et al. (2010 b) American Society of Hematology / American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 116: 4045–4059.
47. Rizzo J.D. Lichtin A.E. Woolf S.H. Seidenfeld J. Bennett C.L. Cella D. et al. (2002) Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 100: 2303–2320.
48. Sepandj F. Jindal K. West M. Hirsch D. (1996) Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients. Nephrol Dial Transplant 11: 319–322.
49. Spahn D.R. Moch H. Hofmann A. Isbister J.P. (2008) Patient blood management: the pragmatic solution for the problems with blood transfusions. Anesthesiology 109: 951–953.
50. Steensma D.P. (2011) Art of oncology: new voices wanted. J Clin Oncol 29: 3343–3344.
51. Steensma D.P. Sloan J.A. Dakhil S.R. Dalton R. Kahanic S.P. Prager D.J. et al. (2011) Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol 29: 97–105.
52. Steinmetz H.T. Tsamaloukas A. Schmitz S. Wiegand J. Rohrberg R. Eggert J. et al. (2010) A new concept for the differential diagnosis and therapy of anaemia in cancer patients. Support Care Cancer 19: 261–269.
53. Steinmetz T. Hellmich M. Neise M. Aldaud A. Lerchenmuller C. Tsamaloukas A. et al. (2007) Prediction of the responsiveness to treatment with erythropoiesis-stimulating factors: a prospective clinical study in patients with solid tumors. Oncologist 12: 748–755.
54. Steinmetz T. Totzke U. Schweigert M. Mittermuller J. Nawka S. Tesch H. et al. (2011) A prospective observational study of anaemia management in cancer patients - results from the German Cancer Anaemia Registry. Eur J Cancer Care (Engl) 20: 493–502.
55. Steinmetz T. Totzke U. Soling U. Groschek M. Mittermuller J. Schweigert M. et al. (2008) Hemoglobin levels that trigger erythropoiesis-stimulating agent treatment decisions for cancer-associated anemia–examination of practice in Germany. Curr Med Res Opin 24: 2751–2756.
56. Steinmetz T. Tschechne B. Virgin G. Klement B. Franzem M. Wamhoff J. et al. (2011) Ferric Carboxymaltose for the Correction of Cancer- and Chemotherapy-associated Anemia in Clinical Practice. London: EHA.
57. Suominen P. Mottonen T. Rajamaki A. Irjala K. (2000) Single values of serum transferrin receptor and transferrin receptor ferritin index can be used to detect true and functional iron deficiency in rheumatoid arthritis patients with anemia. Arthritis Rheum 43: 1016–1020.
58. Thomas C. Kobold U. Balan S. Roeddiger R. Thomas L. (2011) Serum hepcidin-25 may replace the ferritin index in the Thomas plot in assessing iron status in anemic patients. Int J Lab Hematol 33: 187–193.
59. Thomas C. Thomas L. (2002) Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem 48: 1066–1076.
60. Verdon F. Burnand B. Stubi C.L. Bonard C. Graff M. Michaud A. et al. (2003) Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trial. BMJ 326: 1124.
61. Waters J.S. O'Brien M.E. Ashley S. (2002) Management of anemia in patients receiving chemotherapy. J Clin Oncol 20: 601–603.
62. Weiss G. Goodnough L.T. (2005) Anemia of chronic disease. N Engl J Med 352: 1011–1023.